A groundbreaking meta-analysis published in Neurology reveals that tenecteplase is more effective than alteplase in treating ischemic strokes, leading to better recovery outcomes.
Key Findings:
- Tenecteplase increases the likelihood of excellent recovery by 5% compared to alteplase.
- Tenecteplase reduces disability by 10% three months after stroke.
- Both drugs offer similar chances of good recovery.
- Tenecteplase shows superior efficacy with minimal additional risk.
Study Insights:
Researchers analyzed 11 studies, involving 7,545 participants, comparing tenecteplase and alteplase treatment within 4.5 hours of stroke onset.
Expert Perspective:
“Our meta-analysis shows that tenecteplase is superior to alteplase with a greater chance of excellent recovery and reduced disability.” – Georgios Tsivgoulis, MD, PhD, MSc
Implications:
- Tenecteplase may become the preferred treatment option for ischemic strokes.
- FDA approval for tenecteplase in ischemic stroke treatment may be warranted.
- Further research should explore optimal treatment protocols and patient selection.
Reference:
Tsivgoulis et al. (2024). Tenecteplase versus alteplase for acute ischemic stroke: A systematic review and meta-analysis. Neurology. Published online October 16, 2024.
Share Your Thoughts:
How will this breakthrough impact stroke treatment and recovery?
